End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
41.6 CNY | -0.86% | -3.59% | -42.83% |
Apr. 17 | Interest Rate Outlooks Quell Asian Stock Markets | MT |
Apr. 11 | Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-42.83% | 16.35B | A- | ||
-2.07% | 104B | B+ | ||
+1.78% | 97.42B | B+ | ||
+0.79% | 22.2B | B | ||
-17.79% | 21.23B | B+ | ||
-11.11% | 18.33B | A- | ||
-16.58% | 15.06B | B | ||
+3.61% | 13.98B | C+ | ||
+33.44% | 11.66B | C+ | ||
-26.47% | 8.22B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603259 Stock
- Ratings WuXi AppTec Co., Ltd.